Cancer and Drug Development Terms A Accelerated Approval Advisory Committees B Biologics License Applications (BLAs) Biomarkers Breakthrough Therapy C Cancer CBER Clinical Benefit Clinical Trials Clinical Trial Endpoints Companion Diagnostics Comparative Effectiveness D Drug Safety E Expedited Review Programs Priority Review Fast Track Breakthrough Therapy Accelerated Approval F Fast Track FDA First-line Therapy G Generic Drugs Genetic Medicine I Immunotherapy Investigational New Drug Application (IND) L Label Lung-MAP M Market Exclusivity Master Protocol N National Institutes of Health (NIH) National Cancer Institute (NCI) New Drug Applications (NDAs) Next Generation Sequencing (NGS) O Off-Label Use Oncologic Drugs Advisory Committee (ODAC) Orphan Drugs P Patents PCORI PDUFA Personalized Medicine Pivotal Trial Placebo Post-Market Clinical Trials Priority Review R Randomized Clinical Trials S Second-Line Therapy Single-Arm Clinical Trials Standard of Care T Target Population Targeted Therapies Toxicity Trial Design U Unmet Medical Need User Fees
